Olivier is an accomplished antibody engineer with more than 30-year experience having worked for biotech (MRC collaborative centre and NovImmune) and pharma companies (Pierre Fabre, Merck Serono and Vetoquinol). Co-inventor of three marketed therapeutic antibodies, Tysarbri, Bavencio and Gamifant. Co-founder of the technology company Deeptope. Olivier has expertise in antibody
CEO, AM-Pharma Erik brings over 25 years’ experience and serves as CEO at AM-Pharma since 2011. Erik is Chairman of Step Pharma and co-founder and previous (executive) Chairman of Lava Therapeutics (NASDAQ: LVTX), co-founder and previous (executive) Chairman of Heatmatrix Group (sold to BosNieuwkerk) and was board member of Lead
Jean-François has been working in the field of immunology for 25-yr + including 18 years for several biotech and pharmaceutical companies (Serono Pharmaceutical, Merck Serono SA, Merck KGaA, Fresenius-Kabi, and GeNeuro SA). He has expertise in the development of biologics for FiM readiness including selection of PoC studies to serve autoimmune,
Fellow in Cardiology, Research Associate Giuseppina has a longstanding research experience in the role of CD31 in vascular biology and immunology. She works both as a cardiologist and a research scientist at the University Hospital Bichat, in Paris. Giuseppina completed her medical studies at the Catholic University of Rome, obtained
Giuseppina has a longstanding research experience in the role of CD31 in vascular biology and immunology. She works both as a cardiologist and a research scientist at the University Hospital Bichat, in Paris. Giuseppina completed her medical studies at the Catholic University of Rome, obtained a PhD in experimental medicine
Professor and head of the doctoral school in Immunology at the University Paris Cité, Antonino leads the Laboratory for Vascular Translational Science, INSERM U1148, in Paris. Antonino Nicoletti obtained a PhD on inflammation in hypertension in Paris and performed a postdoc at the Karolinska Institute in Stockholm where he demonstrated
Associate, Pureos Bioventures At Pureos, Ximing is active in deal flow generation, investment due diligence, investment and exit transactions as well as fundraising support. In addition to Tridek-One, Ximing is currently BoD observer at Araris Biotech and Engimmune Therapeutics. He obtained his PhD at the European Molecular Biology Laboratory and
Associate, Bioqube Ventures, Alex joined Bioqube in 2016 as a member of the investment team. He is involved in the entire investment process for both portfolio investments and early stage venture creation as part of Bioqube’s dual investment model, from sourcing deals to advancing investment opportunities and performing due diligence.
Scientific Advisor, Advent Life Sciences Fraser is a neuropharmacologist with almost 30 years of drug discovery and early development experience across a range of therapeutic areas, including neurodegeneration, psychiatry, inflammation, gastrointestinal and dermatology. He has a wide C-suite experience in multiple biotech startups and held leadership roles at Shire, AstraZeneca,
Investment Director, Life Sciences, Bpifrance Investissements Since 2014 at Bpifrance Investissements, Benoit has been involved in a dozen investment deals and current board member positions include Alentis, Dynacure, Igyxos, Meiogenix and BrainEver. Prior to this, he gained experience in various biotech roles, co-discovered a vaccine candidate, and developed an antibody